Kala Pharmaceuticals, Inc. (KALA) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Kala Pharmaceuticals, Inc. (KALA) Bundle
Explore the financial outlook of Kala Pharmaceuticals, Inc. (KALA) with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to calculate the intrinsic value of Kala Pharmaceuticals, Inc. (KALA) and refine your investment approach.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.1 | 6.4 | 11.2 | 3.9 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 4.74 | 76.67 | -65.37 | -100 | -20.99 | -20.99 | -20.99 | -20.99 | -20.99 |
| EBITDA | -83.3 | -92.9 | -132.0 | -36.7 | -36.1 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -1370.61 | -1460.26 | -1173.99 | -942.86 | 100 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | 2.6 | 2.8 | 2.3 | .9 | .3 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 43.07 | 44.58 | 20.18 | 22.1 | 100 | 45.98 | 45.98 | 45.98 | 45.98 | 45.98 |
| EBIT | -85.9 | -95.7 | -134.2 | -37.6 | -36.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -1413.68 | -1504.84 | -1194.17 | -964.95 | 100 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 85.4 | 153.5 | 92.1 | 70.5 | 50.9 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 13.1 | 9.9 | 17.5 | 6.5 | .2 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 215.64 | 154.89 | 155.29 | 166.93 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | 4.6 | 5.2 | 8.6 | 7.7 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 76.52 | 82.19 | 76.86 | 197.12 | 100 | 87.11 | 87.11 | 87.11 | 87.11 | 87.11 |
| Accounts Payable | 2.5 | 1.7 | 2.8 | 2.3 | .9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 41.46 | 27.1 | 24.72 | 60.35 | 100 | 50.73 | 50.73 | 50.73 | 50.73 | 50.73 |
| Capital Expenditure | -1.3 | -1.9 | -.9 | -.3 | -.6 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -21.98 | -30.52 | -7.88 | -8.04 | 100 | -13.69 | -13.69 | -13.69 | -13.69 | -13.69 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -92.8 | -102.8 | -143.3 | -.2 | -36.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -106.8 | -100.0 | -151.9 | 11.9 | -24.2 | -.7 | .0 | .0 | .0 | .0 |
| WACC, % | 12.63 | 12.63 | 12.63 | 1.77 | 12.63 | 10.46 | 10.46 | 10.46 | 10.46 | 10.46 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -15 | |||||||||
| Equity Value | 14 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | 5.74 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real KALA financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the highlighted cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe the effect of your inputs on Kala Pharmaceuticals' valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step guidance.
Key Features
- Customizable Financial Inputs: Adjust essential parameters such as revenue projections, operating margins, and research & development expenses.
- Instant DCF Valuation: Automatically computes intrinsic value, net present value (NPV), and additional financial metrics.
- High-Precision Analysis: Leverages Kala Pharmaceuticals' actual financial data for accurate valuation results.
- Effortless Scenario Testing: Easily evaluate various assumptions and analyze different financial outcomes.
- Efficiency Booster: Streamline the valuation process by avoiding the creation of intricate financial models from the ground up.
How It Works
- Download: Get the pre-configured Excel file featuring Kala Pharmaceuticals, Inc. (KALA) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and compare results instantly.
- Make Decisions: Leverage the valuation findings to inform your investment approach.
Why Choose This Calculator for Kala Pharmaceuticals, Inc. (KALA)?
- Accurate Data: Utilize real Kala Pharmaceuticals financials for dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations remove the hassle of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: An intuitive design and clear, step-by-step guidance ensure accessibility for all users.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for analyzing investments in Kala Pharmaceuticals, Inc. (KALA).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the company.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Kala Pharmaceuticals, Inc. (KALA).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech firms like Kala Pharmaceuticals, Inc. (KALA) are valued in the marketplace.
What the Template Contains
- Preloaded KALA Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.